Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4196 - Survival Patterns for Different Types of Cancers in the United States (1973-2012)


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Bioethical Principles and GCP;  Cancer Prevention


Mohamed Gouda


Annals of Oncology (2017) 28 (suppl_5): v511-v520. 10.1093/annonc/mdx385


M.A. Gouda

Author affiliations

  • Department Of Clinical Oncology, Faculty of Medicine - Menoufia University, 32511 - Shebin El Kom/EG


Abstract 4196


Most studies addressing survival patterns focus on 5-years survival data due to difficulties in long-term patients’ follow up. The aim of this study was to explore data on survival making use of the main advantage of SEER (National Cancer Institute Surveillance, Epidemiology, and End Results) program; that is long-term follow up of patients’ records. This enabled reporting 5-years relative survival, 10-years relative survival, and 20-years relative survival for different types of cancers. Survival trends as a function of time and tumor types were also provided.


SEER*Stat version 8.3.4 was used for data acquisition and analysis, where (SEER 18 Regs Nov 2015 Submission) database was used as the data source. Only cases diagnosed between 1973-2012 with malignant behavior, known age, and microscopic confirmation were included. Relative survival was calculated using Ederer II method. Tumors were classified according to ICD-O-3 into either solid malignancies (8000/3-9581/3) or hematological malignancies (9590/3+).


Cancer cases diagnosed between 1973 and 2012 showed a 5-years relative survival of 64.6% (CI: 64.5%-64.6%), a 10-year relative survival of 58.7% (CI: 58.6%-58.7%), and a 20-years relative survival of 51.4% (CI:51.3%-51.5%). All of these percentages were much higher with solid malignancies than hematological ones [Table].Table:

1469P showing relative survival data as a function of time and tumor type

All Cases
5-Year RS51%57.8%65.7%68.9%64.6%
10-Year RS43.6%51.1%60.5%63.7%58.7%
20-Year RS36.9%44.4%54.1%51.4%
Solid Malignancies
5-Year RS51.8%58.7%66.6%69.2%65.2%
10-Year RS44.8%52.4%61.8%64.4%59.7%
20-Year RS38.3%46%55.6%52.7%
Hematological Malignancies
5-Year RS42.4%48.4%56.2%65.5%58.1%
10-Year RS30.9%37.5%47.5%56.6%48%
20-Year RS22.7%29.4%38.6%37.9%


Long-term follow up data were suggestive of 20-years relative survival of 51.4% for all cancers. Data were also suggestive of improved relative survival over time. Unexpectedly, hematological malignancies, despite most of them being thought of as curable ones, appeared to have lower relative survival than solid tumors.

Clinical trial identification


Legal entity responsible for the study

Mohamed Alaa Gouda




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.